Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...
Publications
2 shownNivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with prev...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 4,280
External Links
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.